Cargando…

Complement blockade with eculizumab to treat acute symptomatic humoral rejection after heart transplantation

Antibody‐mediated rejection (AMR) is a major barrier preventing successful discordant organ xenotransplantation, but it also occurs in allotransplantation due to anti‐HLA antibodies. Symptomatic acute AMR is rare after heart allograft but carries a high risk of mortality, especially >1 year after...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yerly, Patrick, Rotman, Samuel, Regamey, Julien, Aubert, Vincent, Aur, Stefania, Kirsch, Matthias, Hullin, Roger, Pascual, Manuel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9285545/ https://www.ncbi.nlm.nih.gov/pubmed/35001433 http://dx.doi.org/10.1111/xen.12726

Ejemplares similares

Body composition and maximal exercise capacity after heart transplantation
por: Regamey, Julien, et al.
Publicado: (2021)

Cardiac Surgery in Advanced Heart Failure
por: Hullin, Roger, et al.
Publicado: (2022)

Clinical Utility and Potential Cost Savings of Pharmacologic Monitoring of Eculizumab for Complement-Mediated Thrombotic Microangiopathy
por: Sridharan, Meera, et al.
Publicado: (2022)

Complement blockade with eculizumab for treatment of severe Coronavirus Disease 2019 in pregnancy: A case series
por: Burwick, Richard M., et al.
Publicado: (2022)

Initial experience with isotropic 3D cardiac T(2) mapping for the monitoring of cardiac allograft rejection
por: van Heeswijk, Ruud B, et al.
Publicado: (2016)

Decongestion improving right heart function ameliorates prognosis after an acute heart failure episode
por: Hullin, Roger, et al.
Publicado: (2022)

Free-breathing T(2 )mapping at 3T for the monitoring of cardiac allograft rejection: initial results
por: van Heeswijk, Ruud B, et al.
Publicado: (2014)

Red cell distribution width and mortality in acute heart failure patients with preserved and reduced ejection fraction
por: Sotiropoulos, Konstantinos, et al.
Publicado: (2016)

Three-Dimensional Self-Navigated T2 Mapping for the Detection of Acute Cellular Rejection After Orthotopic Heart Transplantation
por: van Heeswijk, Ruud B., et al.
Publicado: (2017)

Complement activation and effect of eculizumab in scleroderma renal crisis
por: Devresse, Arnaud, et al.
Publicado: (2016)

Eculizumab treatment alters the proteometabolome beyond the inhibition of complement
por: Nelke, Christopher, et al.
Publicado: (2023)

Non‐severe aortic regurgitation increases short‐term mortality in acute heart failure with preserved ejection fraction
por: Abdurashidova, Tamila, et al.
Publicado: (2020)

Eculizumab for complement mediated thrombotic microangiopathy in sickle cell disease
por: Chonat, Satheesh, et al.
Publicado: (2020)

Eculizumab and Complement Activation in Anti−glomerular Basement Membrane Disease
por: Nithagon, Pravarut, et al.
Publicado: (2021)

Eculizumab improves fatigue in refractory generalized myasthenia gravis
por: Andersen, Henning, et al.
Publicado: (2019)

Disseminated Cryptococcosis Following Eculizumab Therapy: Insight Into Pathogenesis
por: Lortholary, Olivier, et al.
Publicado: (2023)

In vivo Treg expansion under costimulation blockade targets early rejection and improves long‐term outcome
por: Schwarz, Christoph, et al.
Publicado: (2021)

Complement gene variant effect on relapse of complement-mediated thrombotic microangiopathy after eculizumab cessation
por: Acosta-Medina, Aldo A., et al.
Publicado: (2022)

Case Report: Neonatal Unexplained HUS Treated With Complement Inhibitor Eculizumab
por: Kelen, Dorottya, et al.
Publicado: (2021)

Complement inhibitor eculizumab in thrombotic microangiopathy: Single‐center case series
por: Vitkauskaitė, Monika, et al.
Publicado: (2022)

Eculizumab for the Treatment of Severe Antibody-Mediated Rejection: A Case Report and Review of the Literature
por: Tran, Duy, et al.
Publicado: (2016)

Adrenergic Receptor Polymorphism and Maximal Exercise Capacity after Orthotopic Heart Transplantation
por: Métrich, Mélanie, et al.
Publicado: (2016)

Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell–mediated glioma rejection
por: vom Berg, Johannes, et al.
Publicado: (2013)

Eculizumab for Thrombotic Microangiopathy Associated with Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation
por: Lanfranco, Luca, et al.
Publicado: (2017)

Eculizumab as a New Treatment for Severe Acute Post-infectious Glomerulonephritis: Two Case Reports
por: Chehade, Hassib, et al.
Publicado: (2021)

Eculizumab as rescue therapy for atypical hemolytic uremic syndrome with normal platelet count
por: Dorresteijn, Eiske M., et al.
Publicado: (2012)

Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome
por: Vilalta, Ramon, et al.
Publicado: (2012)

Eculizumab use in patients with pneumococcal-associated hemolytic uremic syndrome and kidney outcomes
por: Konopásek, Patrik, et al.
Publicado: (2023)

Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab
por: Wijnsma, Kioa Lente, et al.
Publicado: (2019)

Acute Allograft Rejection: Cellular and Humoral Processes
por: Martinu, Tereza, et al.
Publicado: (2011)

Pathology of Lung Rejection: Cellular and Humoral Mediated
por: Roden, Anja C., et al.
Publicado: (2018)

Acquired thrombotic thrombocytopenic purpura with isolated CFHR3/1 deletion—rapid remission following complement blockade
por: Bitzan, Martin, et al.
Publicado: (2018)

The use of the complement inhibitor eculizumab (Soliris®) for treating Korean patients with paroxysmal nocturnal hemoglobinuria
por: Kim, Jin Seok, et al.
Publicado: (2010)

Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19
por: Laurence, Jeffrey, et al.
Publicado: (2020)

Efficacy of Eculizumab in Coexisting Complement C3 Glomerulopathy and Atypical Hemolytic Uremic Syndrome
por: Busutti, Marco, et al.
Publicado: (2020)

A Computational Model of Linguistic Humor in Puns
por: Kao, Justine T., et al.
Publicado: (2015)

Humoral immunostimulation. IV. Role of complement
Publicado: (1975)

Successful Pregnancies During Ongoing Eculizumab Therapy in Two Patients With Complement-Mediated Thrombotic Microangiopathy
por: Haninger-Vacariu, Natalja, et al.
Publicado: (2020)

Complement C3 mutation causing atypical hemolytic uremic syndrome successfully treated with eculizumab
por: Ellithi, Moataz, et al.
Publicado: (2021)

Complement-Mediated Thrombotic Microangiopathy Associated with Lupus Nephritis Treated with Eculizumab: A Case Report
por: Torres, Everardo Arias, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6scj9ma2ief3sin8ehv0br3jib